Skip to main content
Log in

Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series

  • Original article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Recent reports have raised concerns about low-energy subtrochanteric and diaphyseal femoral fractures after long-term bisphosphonate treatment, which may be associated with severely suppressed bone turnover (SSBT). However, diaphyseal femoral fractures without bisphosphonate treatment have also been reported in patients with severely curved femur, which are commonplace in the elderly. The purpose of this study was therefore to investigate associations between occurrence of such fractures, bisphosphonate use, and curvature of the femur. Nine consecutive elderly patients treated for low-energy diaphyseal femoral fractures between 2005 and 2010 were retrospectively reviewed. Three patients sustained bilateral fractures. Eight patients were administered bisphosphonates and one patient was administered raloxifene. Duration of osteoporosis treatment, type of fractures, surgical procedure, cortical thickness and curvature of opposite femur were evaluated. The cortical thickness and femoral curvature were further compared with those of 24 control subjects without fractures. The mean duration of drug administration was 3.6 years. All fractures showed similar X-ray patterns of simple transverse fracture with medial spike. Only one femur showed thickening of the femoral cortex. One case was treated with locking plate fixation, while the other cases were operated with intramedullary nails (9 antegrade nails, 2 retrograde nails). One femur treated with retrograde nail showed delayed bone union. The femoral curvature was significantly higher in the low-energy fracture group than the control group (P < 0.01); however, cortical thickness did not show a significant difference between the groups. In addition to SSBT, increased femoral curvature might be a causative factor for low-energy diaphyseal femoral fracture in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Cranney A, Wells G, Willan A (2002) Meta-analysis of therapies for postmenopausal osteoporosis. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508–516

    Article  PubMed  CAS  Google Scholar 

  2. Papapoulas SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE (2005) Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporor Int 16:468–474

    Article  Google Scholar 

  3. Cranney A, Tugwell P, Adachi J (2002) Meta-analysis of therapies for postmenopausal osteoporosis. Meta-analysis of risedronate for the treatment of postmenopausal women. Endocr Rev 23:517–523

    Article  PubMed  CAS  Google Scholar 

  4. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fractures in elderly women. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  5. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565

    Article  PubMed  CAS  Google Scholar 

  6. Abrahamsen B (2010) Bisphosphonates adverse effects, lessons from large databases. Curr Opin Rheumatol 22:404–409

    Article  PubMed  CAS  Google Scholar 

  7. Bamias A, Terpos E, Dimopoulos MA (2010) Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatment. Onkologie 33:288–289

    Article  PubMed  Google Scholar 

  8. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301

    Article  PubMed  CAS  Google Scholar 

  9. Cheung RKH, Leung KK, Lee KC, Chow TC (2007) Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 13:485–489

    PubMed  Google Scholar 

  10. Neviaser AS, Lane JM, Lenart BA, Edobar-Osula F, Lorich DG (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350

    Article  PubMed  Google Scholar 

  11. Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39:224–231

    Article  PubMed  Google Scholar 

  12. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edoba-Osula F, Steele B, van der Meulen MCH, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362

    Article  PubMed  CAS  Google Scholar 

  13. Schilcher J, Aspenberg P (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthopaedica 80:413–415

    Article  PubMed  Google Scholar 

  14. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates. A case series from a Swiss University Hospital. Drug Saf 32:775–785

    Article  PubMed  CAS  Google Scholar 

  15. Schneider JP (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64:18–23

    PubMed  Google Scholar 

  16. Burr DB, Diab T, Koivunemi A, Koivunemi M, Allen MR (2009) Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res 27:1288–1292

    Article  PubMed  CAS  Google Scholar 

  17. Isaacs JD, Shidiak L, Harris IA, Szomor ZL (2010) Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop Relat Res 468:3384–3392

    Article  PubMed  Google Scholar 

  18. Taniguchi M, Shiode H, Sakamoto H, Murakami H, Matsumoto Y, Matsushita M (2009) Three cases of atypical fracture of the diaphysis in bisphosphonate therapy (in Japanese). Chubuseisaisi 52:661–662

    Google Scholar 

  19. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44

    Article  PubMed  CAS  Google Scholar 

  20. Aspenberg P, Schilcher J, Fahlgren A (2010) Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment, frozen bone with remodeling at the crack. Acta Orthop 81:460–462

    Article  PubMed  Google Scholar 

  21. Shane E, Burr D, Ebeling PR, Adler RA, Abrahamsen B et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 25:2267–2294

    Article  Google Scholar 

  22. Ozawa H, Ishizuki M, Kitai A, Nagashima M (2004) Fatigue fracture of the femoral shaft in elderly; a case report (in Japanese). Seikeigeka 55:696–699

    Google Scholar 

  23. Hashimoto N, Naka K, Takino T, Muraoka H (2000) Femoral shaft fracture with minor trauma: a report of 2 cases (in Japanese). Higashinihonseisaikaisi 12:362–365

    Google Scholar 

  24. Lambrinoudaki I, Christodoulakos G, Botsis D (2006) Bisphosphonates. Ann N Y Acad Sci 1092:397–402

    Article  PubMed  CAS  Google Scholar 

  25. Kuroda K, Yokokawa A, Nishimura T, Kobayashi T, Inaya H (2010) Femoral shaft fractures in 3 patients on long-term bisphosphonate therapy (in Japanese). Chubuseisaisi 53:463–464

    Google Scholar 

  26. Tan SC, Koh SBJ, Goh SK, Howe TS (2010) Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 22:2211–2212

    Article  PubMed  Google Scholar 

  27. Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra S, Papapoulos SE (2011) Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and femurs. Bone 48:966–971

    Article  PubMed  CAS  Google Scholar 

  28. Unnanuntana A, Ashfaq K, Ton QV, Kleimeyer JP, Lane JM (2012) The effect of long-term alendronate treatment on cortical thickness of the proximal femur. Clin Orthop Relat Res 470:291–298

    Article  PubMed  Google Scholar 

  29. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102

    Article  PubMed  CAS  Google Scholar 

  30. Yoshida K (1976) A biomechanical study of the hip joint and femur (in Japanese). Kurumeigakukaizasshi 44:1046–1069

    Google Scholar 

Download references

Acknowledgments

We wish to thank Drs. Hiroshi Matsuura, and Hidetomo Saito who treated the patients in this study.

Conflict of interest

No disclosures.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoshi Sasaki.

About this article

Cite this article

Sasaki, S., Miyakoshi, N., Hongo, M. et al. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab 30, 561–567 (2012). https://doi.org/10.1007/s00774-012-0358-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-012-0358-0

Keywords

Navigation